Skip to Main Content

Try STAT+ TODAY

microbiome

Most Read

Health Kate Sheridan and Hyacinth Empinado

Watch: What’s the deal with fecal transplants?

Biotech Kate Sheridan

STAT Plus: The field is exploding, but microbiome therapeutics still face a wave of challenges

First Opinion Andrew Thomson, Brian Carpenter and Robert Broadnax

STAT Plus: Developers of microbiome-based drugs face challenges. There are ways to overcome them

Health Kate Sheridan

STAT Plus: OpenBiome to wind down stool bank operations

In the Lab Kate Sheridan

STAT Plus: New research underscores the link between multiple sclerosis and the gut microbiome

Health Kate Sheridan

STAT Plus: One dead, four hospitalized after receiving OpenBiome stool transplants

Health Kate Sheridan

Massachusetts General Hospital oversaw trial that led to the first death from a fecal transplant, a new paper shows

Biotech Megan Thielking

STAT Plus: Biotech, but make it beauty: Startups look to viruses and bacteria for the next generation of skin care

All Coverage

Biotech Kate Sheridan

STAT Plus: New research exploring centenarians’ gut microbiomes reveals a potential clue to their longevity

Biotech Kate Sheridan

STAT Plus: Microbiome therapy companies face the fallout of failed Seres trial

advertisement

Biotech Kate Sheridan

STAT Plus: Seres Therapeutics’ microbiome therapy for ulcerative colitis falls short in Phase 2 trial

Biotech Kate Sheridan

STAT Plus: Nestlé Health Science will split profits from Seres microbiome drug, if it’s approved

Biotech Kate Sheridan

STAT Plus: Microbiome company Finch Therapeutics begins trading publicly, quietly shuffles one of its executives

Biotech Erin Brodwin

STAT Plus: SEC charges co-founders of shuttered microbiome startup uBiome with $60 million fraud

Biotech Kate Sheridan

STAT Plus: Fecal matter transplants could help certain cancer drugs work in more people, study shows

Biotech Kate Sheridan

STAT Plus: Months of limbo at OpenBiome put fecal matter transplants on hold across the country

Biotech Kate Sheridan

STAT Plus: Seres announces positive late-stage results for its microbe-based drug

Biotech Kate Sheridan

STAT Plus: Finch touts positive results for its microbiome pill for C. diff infections

Health Natalya Ortolano

STAT Plus: A patient’s microbiome could have a major impact on how drugs affect them, new research confirms

In the Lab Elizabeth Cooney

STAT Plus: Bacteria are widespread in tumors, forming distinct populations depending on the cancer type

Biotech Kate Sheridan

STAT Plus: ‘Good’ bacteria could help fight a common vaginal infection, new data show

Biotech Kate Sheridan

STAT Plus: Rebiotix unveils positive — but preliminary — data on its microbiome drug for C. diff infections

Health Kate Sheridan

STAT Plus: Within months of birth, some pathogens are detectable in infants’ guts, new research shows

Health Kate Sheridan

STAT Plus: CDC credits a sharp decline in C. diff infections to checklists and better antibiotic stewardship

Biotech Kate Sheridan

STAT Plus: Despite coronavirus disruption, major microbiome companies are cautiously optimistic about upcoming data

Biotech Rebecca Robbins

STAT Plus: Microbial signatures in the blood could offer new avenue for liquid biopsies to detect cancer

Biotech Kate Sheridan

STAT Plus: Microbiome-based drug makers are hoping new late-stage data will pull the field out of the shadows

Biotech Erin Brodwin

STAT Plus: Bankrupt uBiome preliminarily sells patents for 1% of the poop-testing startup’s original valuation

Opinions+ Peter Bak

STAT Plus: Microbiome drug development: a rapidly evolving field

Biotech Kate Sheridan

STAT Plus: After an unprecedented death, FDA is offered divergent forecasts on future of fecal transplants

Biotech Kate Sheridan

STAT Plus: FDA to consider new evidence, risks behind fecal matter transplants for C. diff treatment

Biotech Kate Sheridan

STAT Plus: The next frontier for the microbiome: vaginal fluid transplants that take aim at a common condition

Pharmalot Elizabeth Cooney

STAT Plus: Pharmalittle: Medicare will cover CAR-T; Trump health care overhaul in the wings